Journal article
Challenges in breast cancer clinical trial design in the postgenomic era
S Loi, M Buyse, C Sotiriou, F Cardoso
CURRENT OPINION IN ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2004
Abstract
PURPOSE OF REVIEW: Clinical trials in breast cancer (BC) have seldom taken into consideration molecular heterogeneity, because most have been performed in unselected populations. Hence, their results provide an estimated average benefit for the entire BC population, which may not always be translated to subsets of patients with certain characteristics, let alone to individual patients. Further understanding and acknowledgment of heterogeneity is vital for the development of individualized therapy in BC. New approaches are needed for trial design, patient selection, and choice of endpoints (including surrogate markers). The neoadjuvant setting presents a unique opportunity to test new concept..
View full abstract